Is ILMN Stock Undervalued?

A comprehensive valuation analysis of Illumina Inc (ILMN) examining current multiples, intrinsic value, and comparing to analyst expectations.

Updated January 14, 2026•8 min read•View Full Analysis

Valuation Verdict

→

Fairly Valued

0.0% downside risk

Based on our analysis, Illumina Inc appears to be fairly valued at the current price of $146.99.

Current Valuation Metrics

Valuation ratios help us understand how the market is pricing ILMN relative to its fundamentals. Let's examine the key multiples investors are paying today.

P/E Ratio

33.03

High

P/B Ratio

9.34

High

P/S Ratio

5.27

High

EV/EBITDA

18.52

High

Understanding the Metrics

P/E Ratio: At 33.03x earnings, ILMN is trading above the typical market average of 15-20x.
P/B Ratio: A P/B of 9.34 means investors pay $9.34 for every $1 of book value.
P/S Ratio: The price-to-sales ratio of 5.27 indicates how much investors value each dollar of revenue.
EV/EBITDA: This ratio of 18.52 helps compare ILMN to peers while accounting for debt.

Fair Value Estimate

Using a discounted cash flow (DCF) model, we estimate the intrinsic value of Illumina Inc stock. This fundamental analysis looks at the company's ability to generate future cash flows and discounts them back to today's value.

Current Price

$146.99

Fair Value Estimate

N/A

Unable to calculate a reliable fair value estimate due to insufficient financial data or negative cash flows. This is common for early-stage growth companies or those undergoing restructuring.

Analyst Price Targets

Wall Street analysts provide price targets based on their fundamental research and models. Let's see how the consensus view compares to the current price.

Current Price

$146.99

→

Analyst Target

$131.47

Implied Upside-10.6%

The consensus analyst price target of $131.47 suggests 10.6% downside risk from current levels. Analysts appear cautious on the stock at current levels.

Investment Conclusion

Bottom Line

Illumina Inc (ILMN) appears fairly valued at $146.99, trading in line with our fundamental analysis. The stock may be appropriate for investors seeking exposure to Healthcare without significant valuation risk.

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.